Impact of Post-Transplantation Hypomagnesemia on Long-Term Graft and Patient Survival after Transplantation

Abstract

<b><i>Background:</i></b> Post-transplant hypomagnesemia is commonly observed among patients prescribed calcineurin inhibitor (CNIs). <b><i>Methods:</i></b> We conducted a retrospective single-center analysis (2000–2013, <i>N</i> = 726) to examine the association of hypomagnesemia with long-term patient and allograft outcomes in kidney transplant recipients. A median serum magnesium (Mg) level of all measured Mg levels from 1 month to 1 year posttransplant was calculated. <b><i>Results:</i></b> For every increase in Mg of 0.1 mg/dL, the risk for either graft loss or death, overall mortality, and death with a functioning graft increased by 11%, 14%, and 12%, respectively (<i>p</i> &#x3c; 0.01). In a multivariate model, patients with median Mg level ≥1.7 mg/dL had a reduced overall survival rate (HR 1.57, 95% CI: 1.04–2.38, <i>p</i> = 0.033) compared to those with median Mg level &#x3c;1.7 mg/dL. This association was observed in subgroups of patients above 60 years old, in those who had a slow graft function (SGF) and in females. <b><i>Conclusions:</i></b> Posttransplant hypomagnesemia is associated with better patient and allograft survival up to 10 years posttransplant. This relationship remained significant after accounting for baseline allograft function, presence of SGF and CNI trough levels.